{"id":"biphasic-human-insulin-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product contains 50% soluble (regular) human insulin for immediate postprandial glucose control and 50% isophane (NPH) insulin for basal coverage. The biphasic formulation mimics physiological insulin secretion patterns by delivering quick glucose-lowering action after meals combined with sustained background insulin activity throughout the day.","oneSentence":"Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:05.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06638190","phase":"NA","title":"Influence of the Fruit Matrix on Glucose and Insulin Responses After the Intake of Orange Juice in Healthy Human Males","status":"COMPLETED","sponsor":"María-Teresa García-Conesa","startDate":"2024-10-21","conditions":"Healthy Nutrition","enrollment":25},{"nctId":"NCT06855615","phase":"PHASE4","title":"Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hospital Sultanah Aminah Johor Bahru","startDate":"2020-10-01","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":44},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT01650129","phase":"PHASE3","title":"Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-12-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":83},{"nctId":"NCT01523041","phase":"PHASE1","title":"Comparison of Two Formulations of Biphasic Insulin Aspart 70","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-11-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01527643","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-11-11","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01527552","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11-05","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01527630","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT01620437","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-11-29","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT00775736","phase":"","title":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00612599","phase":"PHASE3","title":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":75},{"nctId":"NCT01536028","phase":"PHASE1","title":"Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT00184574","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":603},{"nctId":"NCT01620333","phase":"PHASE1","title":"Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-02","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01620424","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT01520831","phase":"PHASE1","title":"Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-04","conditions":"Diabetes, Healthy","enrollment":35},{"nctId":"NCT01520818","phase":"PHASE3","title":"Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":666},{"nctId":"NCT01520753","phase":"PHASE3","title":"Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":16},{"nctId":"NCT00834262","phase":"","title":"Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":339},{"nctId":"NCT00755833","phase":"","title":"Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":270},{"nctId":"NCT01865305","phase":"PHASE1","title":"Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01892020","phase":"PHASE4","title":"Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":161},{"nctId":"NCT01242826","phase":"PHASE1","title":"Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-02","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT00627445","phase":"PHASE3","title":"Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT00888732","phase":"PHASE3","title":"A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT00283218","phase":"NA","title":"A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-01","conditions":"Type 1 Diabetes","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"biphasic human insulin 50","genericName":"biphasic human insulin 50","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biphasic human insulin 50 is used to treat conditions such as Type 1 Diabetes, Diabetes, and Type 2 Diabetes. It is a type of insulin that combines a rapid-acting and a longer-acting component, as indicated by its comparison in a clinical trial to insulin aspart and other biphasic insulin aspart formulations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}